list of publications

See ResearcherID


Selected Articles

K. Filarsky, A. Garding, N. Becker, C. Wolf, M. Zucknick, R. Claus, D. Weichenhan, C. Plass, H. Döhner, S. Stilgenbauer, P. Lichter and D. Mertens (2016). „Krüppel-Like Factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling.“ Haematologica, in press, IF 5.814

C.C. Oakes, M. Seifert, Y. Assenov, L. Gu, M. Przekopowitz, A.S. Ruppert, Q. Wang, C. Imbusch, A. Serva, S. Koser, D. Brocks, D. Lipka, O. Bogatyrova, D. Mertens, M. Zapatka, P. Lichter, H. Döhner, R. Küppers, T. Zenz, S. Stilgenbauer, J.C. Byrd and C. Plass (2015). “Progressive epigenetic programming during B cell maturation is reflected in a continuum of epigenetic disease phenotypes in chronic lymphocytic leukemia.” Nature Genetics, in press, IF 29.352

D.A. Landau*, E. Tausch*, A.N. Taylor-Weiner*, C. Stewart, J. Reiter, J. Bahlo, S. Kluth, I. Bozic, M. Lawrence, S. Bottcher, K. Cibulskis, D. Mertens, C. Sougnez, M. Rosenberg, J.M. Hess, S.L. Carter, J. Edelmann, S. Kless, A. Fink, K. Fischer, S. Gabriel, E. Lander,  M. Nowak, H. Dohner, M. Hallek, D. Neuberg**,   G. Getz**, S. Stilgenbauer** and C.J. Wu** (2015). „Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse.” Nature526(7574):525-30, IF 41.456

Bhattacharya, N., M. Reichenzeller, M. Caudron-Herger, S. Haebe, N. Brady, S. Diener, M. Nothing, H. Dohner, S. Stilgenbauer, K. Rippe and D. Mertens (2015). "Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6." Int J Cancer, 136(1):65-73, IF 6.198

Allegra, D., Bilan, V., Garding, A., Döhner, H., Stilgenbauer, S., Kuchenbauer, F., Mertens, D. (2013), Defective DROSHA processing contributes to downregulation of miR-15/-16 in chronic lymphocytic leukemia, Leukemia, 28(1):98-107, IF 10.164

Zenz, T., D. Mertens, R. Kuppers, H. Dohner and S. Stilgenbauer (2010). From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:1: 37-50, IF 29.538


Original Articles

51. K. Filarsky, A. Garding, N. Becker, C. Wolf, M. Zucknick, R. Claus, D. Weichenhan, C. Plass, H. Döhner, S. Stilgenbauer, P. Lichter and D. Mertens (2016). „Krüppel-Like Factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling.“ Haematologica, in press, IF 5.814

50.  C.C. Oakes, M. Seifert, Y. Assenov, L. Gu, M. Przekopowitz, A.S. Ruppert, Q. Wang, C. Imbusch, A. Serva, S. Koser, D. Brocks, D. Lipka, O. Bogatyrova, D. Mertens, M. Zapatka, P. Lichter, H. Döhner, R. Küppers, T. Zenz, S. Stilgenbauer, J.C. Byrd and C. Plass (2015). “Progressive epigenetic programming during B cell maturation is reflected in a continuum of epigenetic disease phenotypes in chronic lymphocytic leukemia.” Nature Genetics, in press, IF 29.352

 49. D.A. Landau*, E. Tausch*, A.N. Taylor-Weiner*, C. Stewart, J. Reiter, J. Bahlo, S. Kluth, I. Bozic, M. Lawrence, S. Bottcher, K. Cibulskis, D. Mertens, C. Sougnez, M. Rosenberg, J.M. Hess, S.L. Carter, J. Edelmann, S. Kless, A. Fink, K. Fischer, S. Gabriel, E. Lander,  M. Nowak, H. Dohner, M. Hallek, D. Neuberg**,   G. Getz**, S. Stilgenbauer** and C.J. Wu** (2015). „Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse.” Nature, 526(7574):525-30, IF 41.456

48. Opel, D., Schnaiter, A., Dodier, D., Jovanovic, M., Gerhardinger, A., Idler, I., Mertens, D., Bullinger, L., Stilgenbauer, S., Fulda, S. (2015). „Targeting inhibitor of apoptosis proteins by Smac mimetic elicits death in poor prognostic subgroups of chronic lymphocytic leukemia.“ Int. J. Cancer, 137(12):2959-70, IF 5.007.

47. Baer, C., Oakes, CC, Ruppert, AS., Claus, R., Kim-Wanner, SZ., Mertens, D., Zenz, T., Stilgenbauer, S., Byrd, JC. and Plass, C. (2015). „Epigenetic silencing of miR-708 enhances NF-kB signaling in chronic lymphocytic leukemia.“ Int J Cancer, 137(6):1352-61, IF 5.007

46. Bhattacharya, N., M. Reichenzeller, M. Caudron-Herger, S. Haebe, N. Brady, S. Diener, M. Nothing, H. Dohner, S. Stilgenbauer, K. Rippe and D. Mertens (2015). "Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6." Int J Cancer, 136(1):65-73,  IF 6.198

45. Stilgenbauer, S., A. Schnaiter, P. Paschka, T. Zenz, M. Rossi, K. Dohner, A. Buhler, S. Bottcher, M. Ritgen, M. Kneba, D. Winkler, E. Tausch, P. Hoth, J. Edelmann, D. Mertens, L. Bullinger, M. Bergmann, S. Kless, S. Mack, U. Jager, N. Patten, L. Wu, M. K. Wenger, G. Fingerle-Rowson, P. Lichter, M. Cazzola, C. M. Wendtner, A. M. Fink, K. Fischer, R. Busch, M. Hallek and H. Dohner (2014). "Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial." Blood, in press. IF 9.060

44. Skorka, K., N. Bhattacharya, P. Wlasiuk, M. Kowal, D. Mertens, A. Dmoszynska and K. Giannopoulos (2014). "Thalidomide regulation of NF-kappaB proteins limits Tregs activity in chronic lymphocytic leukemia." Adv Clin Exp Med 23(1): 25-32., IF 0.293

43. C. Oakes, R. Claus, L. Gu, Y. Assenov, J. Hüllein, M. Zucknick, D. Brocks, O. Bogatyrova, C. Schmidt, L. Rassenti, TJ. Kipps, Mertens, D., P. Lichter, H. Dohner, S. Stilgenbauer, JC. Byrd, T. Zenz and C. Plass (2013) Heterogeneity and evolution of DNA methylation are linked to genetic aberrations in chronic lymphocytic leukemia, Cancer Disvovery,  4(3):348-361, IF 10.143

42. Allegra, D., Bilan, V., Garding, A., Döhner, H., Stilgenbauer, S., Kuchenbauer, F., Mertens, D. (2013), Defective DROSHA processing contributes to downregulation of miR-15/-16 in chronic lymphocytic leukemia, Leukemia, 28(1):98-107, IF 10.164

41. Schnaiter, A., Pascka, P.,  Rossi, M., Zenz, T., Bühler, A., Winkler, D., Cazzola, M., Döhner, K., Edelmann, J., Mertens, D., Kless, S., Mack, S., Busch, E., Hallek, M., Döhner, H., Stilgenbauer, S. (2013), NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG, Blood,122(7):1266-1270, IF 9.060

40. Wei, QX., Claus, R., Hielscher, T., Mertens, D., Raval, A., Oakes, CC., Tanner, ST., de la Chapelle, A., Byrd, JC., Stilgenbauer, S., Plass, C. (2013), Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia, PLOS ONE, 8(1) e55261, IF 4.091

39. Garding, A., Bhattacharya, N., Claus, R., Ruppel, M., Tschuch, C., Filarsky, K., Idler, I., Zucknick, M., Caudron-Herger, M., Oakes, C., Fleig, V., Keklikoglou, I., Allegra, D., Serra, L., Thakurela, S., Tiwari, V., Weichenhan, D., Benner, A., Radlwimmer, B., Zentgraf, H., Wiemann, S., Rippe, K., Plass, C., Döhner, H., Lichter, P. Stilgenbauer, S., Mertens, D. (2013), Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB, PLOS Genetics, 9(4): e1003373, IF 8.694

38. Jebaraj, BMC., Kienle, D., Lechel, A., Mertens, D., Heuberger, M., Ott, D., Rosenwald, A., Barth, T., Möller, P., Zenz, T., Döhner, H., Stilgenbauer, S.. (2013), "Telomere Length in Mantle Cell Lymphoma", Blood121(7):1184-7IF 8.989

34.  Garding, A., Bhattacharya, N., Haebe, S., Mueller, F., Weichenhan, D., Idler, I., Ickstadt, K., Stilgenbauer, S. & Mertens, D. (2013) "TCL1A and ATM are coexpressed in chronic lymphocytic leukemia cells without deletion of 11q." Haematologica, 98(2):269-73. IF 6.416

37. Faber, K., Bullinger, L., Ragu, C., Garding, A., Mertens, D., Miller, C., Martin, D., Walcher, D., Döhner, K., Döhner, H., Claus, R., Plass, C., Sykes, S.M., Lane, S.W., Scholl, C., & Fröhling, S. (2012), “Myeloid leukemogenesis by CDX2 involves repression of KLF4 and deregulated PPAR signalling”, JCI123(1): 299-314, IF 13.069

36. Edelmann, J., Holzmann, K., Miller, F., Winkler, D., Bühler, A., Zenz, T., Bullinger, L., Kühn, M.W.M., Gerhardinger, A., Blöhdorn, J., Radtke, I., Su, X., Ma, J., Pounds, S., Hallek, M., Lichter, P., Korbel, J., Busch, R., Mertens, D., Downing, J.R., Stilgenbauer, S., & Döhner H. (2012), “High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations”, Blood120(24):4783-94, IF 8.989

35. Claus, R., Lucas, D. M., Stilgenbauer, S., Ruppert, A. S., Yu, L., Zucknick, M., Mertens, D., Buhler, A., Oakes, C. C., Larson, R. A., Kay, N. E., Jelinek, D. F., Kipps, T. J., Rassenti, L. Z., Gribben, J. G., Dohner, H., Heerema, N. A., Marcucci, G., Plass, C. & Byrd, J. C. (2012) "Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia." J Clin Oncol, 30(20):2483-91. IF 18.970

33. Grasedieck, S., Scholer, N., Bommer, M., Niess, J. H., Tumani, H., Rouhi, A., Bloehdorn, J., Liebisch, P., Mertens, D., Dohner, H., Buske, C., Langer, C. & Kuchenbauer, F. (2012) "Impact of serum storage conditions on microRNA stability." Leukemia, 26(11):2414-6. IF 8.966

32.  Grzywnowicz, M., Zaleska, J., Mertens, D., Tomczak, W., Wlasiuk, P., Kosior, K., Piechnik, A., Bojarska-Junak, A., Dmoszynska, A. & Giannopoulos, K. (2012) "Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia." PloS one, 7, e35178. IF 4.411

31. Allegra, D. & Mertens, D. (2011) "In-vivo quantification of primary microRNA processing by Drosha with a luciferase based system." Biochemical and biophysical research communications, 406, 501-505. IF 2.595

30. Bhattacharya, N., Diener, S., Idler, I. S., Rauen, J., Habe, S., Busch, H., Habermann, A., Zenz, T., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Nurse-like cells show deregulated expression of genes involved in immunocompetence." Br J Haematol, 154, 349-356. IF 4.597

29. Mohr, J., Helfrich, H., Fuge, M., Eldering, E., Buhler, A., Winkler, D., Volden, M., Kater, A. P., Mertens, D., Te Raa, D., Dohner, H., Stilgenbauer, S. & Zenz, T. (2011) "DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing." Blood, 117, 1622-1632. IF 10.555

28.  Wittig-Blaich, S. M., Kacprzyk, L. A., Eismann, T., Bewerunge-Hudler, M., Kruse, P., Winkler, E., Strauss, W. S., Hibst, R., Steiner, R., Schrader, M., Mertens, D., Sultmann, H. & Wittig, R. (2011) "Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells." Neoplasia, 13, 579-589. IF 5.476

27. Bhattacharya, N., Diener, S., Idler, I. S., Barth, T. F., Rauen, J., Habermann, A., Zenz, T., Moller, P., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood." Leukemia, 25, 722-726. IF 8.296

26.  Bhattacharya, N., Sarno, A., Idler, I. S., Fuhrer, M., Zenz, T., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay." Int J Cancer, 127, 404-411. IF 4.722

25. Philippen, A., Diener, S., Zenz, T., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)." Br J Haematol, 150, 633-636. IF 4.597

24.  Winkler, D., Schneider, C., Zucknick, M., Bogelein, D., Schulze, K., Zenz, T., Mohr, J., Philippen, A., Huber, H., Buhler, A., Habermann, A., Benner, A., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk." Haematologica, 95, 1880-1888. IF 6.416

23.  Zenz, T., Mohr, J., Edelmann, J., Sarno, A., Hoth, P., Heuberger, M., Helfrich, H., Mertens, D., Dohner, H. & Stilgenbauer, S. (2009) "Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway." Leuk Lymphoma, 50, 510-513. IF 2.397

22.  Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Buhler, A., Kienle, D., Winkler, D., Durig, J., van Oers, M. H., Mertens, D., Dohner, H. & Stilgenbauer, S. (2009) "miR-34a as part of the resistance network in chronic lymphocytic leukemia." Blood, 113, 3801-3808. IF 10.555

21.  Giannopoulos, K., Mertens, D., Buhler, A., Barth, T. F., Idler, I., Moller, P., Krober, A., Greiner, J., Chocholska, S., Dmoszynska, A., Rolinski, J., Dohner, H., Stilgenbauer, S. & Schmitt, M. (2009) "The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia." Leukemia, 23, 519-527. IF 8.296

20.  Loeder, S., Zenz, T., Schnaiter, A., Mertens, D., Winkler, D., Dohner, H., Debatin, K. M., Stilgenbauer, S. & Fulda, S. (2009) "A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia." Cancer Res, 69, 8977-8986. IF 7.543

19.  Idler, I., Giannopoulos, K., Zenz, T., Bhattacharya, N., Nothing, M., Dohner, H., Stilgenbauer, S. & Mertens, D. (2009) "Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells." Br J Haematol, 148, 948-950. IF 4.597

18.  Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. & Stilgenbauer, S. (2009) "Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial." Blood, 114, 2589-2597. IF 10.555

17.  Tschuch, C., Schulz, A., Pscherer, A., Werft, W., Benner, A., Hotz-Wagenblatt, A., Barrionuevo, L. S., Lichter, P. & Mertens, D. (2008) "Off-target effects of siRNA specific for GFP." BMC Mol Biol, 9, 60. IF 2.848

16.  Kalla, C., Scheuermann, M. O., Kube, I., Schlotter, M., Mertens, D., Dohner, H., Stilgenbauer, S. & Lichter, P. (2007) "Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B." Eur J Cancer, 43, 1328-1335. IF 4.121

15.  Prowatke, I., Devens, F., Benner, A., Grone, E. F., Mertens, D., Grone, H. J., Lichter, P. & Joos, S. (2007) "Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays." Br J Cancer, 96, 82-88. IF 4.346

14.  Henrich, K. O., Fischer, M., Mertens, D., Benner, A., Wiedemeyer, R., Brors, B., Oberthuer, A., Berthold, F., Wei, J. S., Khan, J., Schwab, M. & Westermann, F. (2006) "Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients." Clin Cancer Res, 12, 131-138. IF 6.747

13.  Kienle, D., Benner, A., Krober, A., Winkler, D., Mertens, D., Buhler, A., Seiler, T., Jager, U., Lichter, P., Dohner, H. & Stilgenbauer, S. (2006) "Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes." Blood, 107, 2090-2093. IF 10.555

12. Adamowicz, M., Radlwimmer, B., Rieker, R. J., Mertens, D., Schwarzbach, M., Schraml, P., Benner, A., Lichter, P., Mechtersheimer, G. & Joos, S. (2006) "Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas." Genes Chromosomes Cancer, 45, 829-838. IF 3.858

11.  Wolf, S., Mertens, D., Pscherer, A., Schroeter, P., Winkler, D., Grone, H. J., Hofele, C., Hemminki, K., Kumar, R., Steineck, G., Dohner, H., Stilgenbauer, S. & Lichter, P. (2006) "Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer." Int J Cancer, 118, 1831-1835. IF 4.722

10.  Mannherz, O., Mertens, D., Hahn, M. & Lichter, P. (2006) "Functional screening for proapoptotic genes by reverse transfection cell array technology." Genomics, 87, 665-672. IF 3.327

9.  Mertens, D., Wolf, S., Tschuch, C., Mund, C., Kienle, D., Ohl, S., Schroeter, P., Lyko, F., Dohner, H., Stilgenbauer, S. & Lichter, P. (2006) "Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism." Proc Natl Acad Sci U S A, 103, 7741-7746. IF 9.432

8.    Kienle, D. L., Korz, C., Hosch, B., Benner, A., Mertens, D., Habermann, A., Krober, A., Jager, U., Lichter, P., Dohner, H. & Stilgenbauer, S. (2005) "Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes." J Clin Oncol, 23, 3780-3792. IF 17.793

7.  Kalla, C., Nentwich, H., Schlotter, M., Mertens, D., Wildenberger, K., Dohner, H., Stilgenbauer, S. & Lichter, P. (2005) "Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes." Genes Chromosomes Cancer, 42, 128-143. IF 3.858

6.  Mertens, D., Wolf, S., Schroeter, P., Schaffner, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2002) "Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia." Blood, 99, 4116-4121. IF 10.555

5.    Korz, C., Pscherer, A., Benner, A., Mertens, D., Schaffner, C., Leupolt, E., Dohner, H., Stilgenbauer, S. & Lichter, P. (2002) "Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes." Blood, 99, 4554-4561. IF 10.555

4.    Wolf, S., Mertens, D., Schaffner, C., Korz, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2001) "B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions." Hum Mol Genet, 10, 1275-1285. IF 7.386

3.    Mertens, D., Wolf, S., Bullinger, L., Ohl, S., Schaffner, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2000) "BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22- p31, BCMSUN-like." Int J Cancer, 88, 692-697. IF 4.722

2.    Bullinger, L., Leupolt, E., Schaffner, C., Mertens, D., Bentz, M., Lichter, P., Dohner, H. & Stilgenbauer, S. (2000) "BCL10 is not the gene inactivated by mutation in the 1p22 deletion region in mantle cell lymphoma." Leukemia, 14, 1490-1492. IF 8.296

1.    Lammer, C., Wagerer, S., Saffrich, R., Mertens, D., Ansorge, W. & Hoffmann, I. (1998) "The cdc25B phosphatase is essential for the G2/M phase transition in human cells." J Cell Sci, 111 ( Pt 16), 2445-2453. IF 6.144

 

Reviews

16. Mertens, D. and S. Stilgenbauer (2014). "Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?" J Clin Oncol, 32(9): 869-872, IF 18.038

15. Tausch, E., Mertens, D. and Stilgenbauer, S. (2014). "Advances in treating chronic lymphocytic leukemia." F1000Prime Reports,  6(65), no IF

14. Grasedieck, S., Sorrentino, A., Langer, C., Buske, C., Döhner, H., Mertens, D., Kuchenbauer, F. (2013) "Circulating microRNAs in Hematological Diseases: Principles, Challenges and Perspectives." Blood, 121(25):4977-4984, IF 9.989

13. Kugler, S., Schnaiter, A., Stilgenbauer, S. & Mertens, D. (2013) "Missing the Notch in NOTCH1" Leukemia & Lymphoma, 54(8):1579-1580. IF 2.580

12. Mertens, D. & Stilgenbauer, S. (2012) "CLL and deletion 13q14: merely the miRs?" Blood, 119, 2974-2975. IF 10.558

11. Idler, I., Bhattacharya, N., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Immune modulatory agents in hematopoietic malignancies." Cancer treatment reviews, 37 Suppl 1, S2-7. IF 6.811

10. Schnaiter, A., Mertens, D. & Stilgenbauer, S. (2011) "Genetics of chronic lymphocytic leukemia." Clinics in laboratory medicine, 31, 649-658, ix. IF 1.966

9. Stilgenbauer, S. & Mertens, D. (2011) "Toward chemotherapy-free treatment of CLL." Blood, 118, 3451-3452. IF 10.558

8.   Mertens, D., Bullinger, L. & Stilgenbauer, S. (2011) "Chronic lymphocytic leukemia--genomics lead the way." Haematologica, 96, 1402-1405. IF 6.532

7.   Giannopoulos, K., Mertens, D., Stilgenbauer, S. (2011), Treating chronic lymphocytic leukemia with Thalidomide and Lenalidomide, Current Opinion in Pharmacotherapy, 12(18):2857-64, IF 2.403

6.    Zenz, T., Mertens, D., Dohner, H. & Stilgenbauer, S. (2011) "Importance of genetics in chronic lymphocytic leukemia." Blood reviews, 25, 131-137. IF 10.558

5.    Zenz, T., Mertens, D. & Stilgenbauer, S. (2010) "Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia." Haematologica, 95, 1441-1443. IF 6.416

4.    Zenz, T., Frohling, S., Mertens, D., Dohner, H. & Stilgenbauer, S. (2010) "Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)." Best Pract Res Clin Haematol, 23, 71-84. IF 3.134

3.    Zenz, T., Mertens, D., Kuppers, R., Dohner, H. & Stilgenbauer, S. (2010) "From pathogenesis to treatment of chronic lymphocytic leukaemia." Nat Rev Cancer, 10, 37-50. IF 29.538

2.    Mertens, D., Philippen, A., Ruppel, M., Allegra, D., Bhattacharya, N., Tschuch, C., Wolf, S., Idler, I., Zenz, T. & Stilgenbauer, S. (2009) "Chronic lymphocytic leukemia and 13q14: miRs and more." Leuk Lymphoma, 50, 502-505. IF 2.397

1.    Zenz, T., Mertens, D., Dohner, H. & Stilgenbauer, S. (2008) "Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications." Leuk Lymphoma, 49, 864-873. IF 2.397

Book Chapters

2.    Bilan, V., Allegra, D., Kuchenbauer, F., Mertens, D. (2014) "In vivo processing assay based on a dual-luciferase reporter system to evaluate DROSHA enzymatic activity." in miRNA Maturation, Arenz, C., ed. (Humana Press), 87-93, 2014

1.     Bloehdorn, J., Rouhi, A., Dhanyamraju, P., Krowiorz, K., Schneider, E., Langer,C., Mertens, D., Stilgenbauer, S., Kuchenbauer, F. (2013) "MicroRNAs in hematologic malignancies." in Non-coding RNAs and Cancer, Fabbri, M., ed. (Springer Science & Business Media), chapter 5.2